Australia's regenerative medicine company, Mesoblast Limited (ASX:MSB)(USOTC:MBLTY)(PINK:MEOBF), announced that the United States Food and Drug Administration (US FDA) had cleared an Investigational New Drug (IND) submission by its US-based sister company, Angioblast Systems Inc., to commence a Phase 2 trial of the stem cell platform technology for treating patients with congestive heart failure. Major New Market Opportunity Key Points: - FDA clears Phase 2 clinical trial for congestive heart failure - Third IND submission cleared for platform stem cell technology - Multiple centres in US to participate - Major milestone hit on time and within budget The trial will enrol 60 patients with heart failure at multiple major centres across the US. Fifteen patients will serve as controls and 45 will receive one of three doses of the...
[read full story]
Your Web Site
